	Application No.	Applicant(s)
Notice of Allowability	10/529,748 <b>Examiner</b>	ZLOKOVIC ET AL.  Art Unit
	- LAGITIMO	/ II Com
	Daniel E. Kolker	1649
The MAILING DATE of this communication appeal claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in the or other appropriate communic IGHTS. This application is sub-	is application. If not included cation will be mailed in due course. <b>THIS</b>
1. $\boxtimes$ This communication is responsive to $2/2/11$ .		
2. X The allowed claim(s) is/are <u>6,13,16-18,30,34,37 and 38</u> .		
<ul> <li>3. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> <li>a) All b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents have been received.</li> <li>2. Certified copies of the priority documents have been received in Application No.</li> <li>3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* Certified copies not received:</li> <li>Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements</li> </ul>		
noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
5. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) hereto or 2) to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1. Notice of References Cited (PTO-892)		mal Patent Application
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ⊠ Interview Sum Paper No./Ma	mary (PTO-413), ail Date <u>20110209</u> .
3. Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date	7. 🛛 Examiner's An	
Examiner's Comment Regarding Requirement for Deposit of Biological Material		atement of Reasons for Allowance
	9.	
/Daniel E Kolker/ Primary Examiner, Art Unit 1649 February 14, 2011		

Application/Control Number: 10/529,748 Page 2

Art Unit: 1649

## **EXAMINER'S AMENDMENT**

1. The remarks filed 2 February 2011 have been entered. Claims 6, 13, 16-18, 25, 29-30, and 34-38 are pending and under examination.

2. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Gary Tanigawa on 14 February 2011.

3. The application has been amended as follows:

In the claims:

Claim 6 has been re-written as follows:

A method of protecting one or more cell types of a human subject's nervous system, comprising

administering to a human subject an amount of human protein S effective to provide neuroprotection,

wherein no protein C or activated protein C is administered,

and wherein the human subject has a brain injury caused by cerebral ischemia, cerebral hypoxia, cerebral re-oxygenation or any combination thereof.

Cancel claims 25, 29, and 35-36.

Claim 30 has been re-written as follows:

A method of treating stroke in a human subject, comprising administering to a human subject an amount of human protein S effective to treat stroke, wherein no protein C or activated protein C is administered, and wherein the human subject has experienced stroke.

Application/Control Number: 10/529,748 Page 3

Art Unit: 1649

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Daniel E. Kolker whose telephone number is (571)272-3181. The examiner can normally be reached on Mon - Fri 8:30AM - 5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Stucker can be reached on (571) 272-0911. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Daniel E Kolker/
Primary Examiner, Art Unit 1649
February 14, 2011